Trial Profile

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Metastatic Breast Cancer

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nivolumab (Primary) ; Paclitaxel (Primary) ; Carboplatin; Gemcitabine
Indications Adenocarcinoma; Advanced breast cancer; Non-small cell lung cancer; Pancreatic cancer
Focus Adverse reactions
Sponsors Bristol-Myers Squibb; Celgene Corporation

18 Jun 2020 Results from advanced pancreatic cancer cohort published in the Clinical Cancer Research
19 Jan 2019 Results assesing nivolumab + nab-paclitaxel + gemcitabine in advanced pancreatic cancer (n=50) presented at the 2019 Gastrointestinal Cancers Symposium
25 Oct 2018 Status changed from active, no longer recruiting to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com